SSA
AMED

Schonfeld Strategic Advisors’s Amedisys AMED Stock Holding History

Schonfeld Strategic Advisors’s Portfolio AMED Stock Details AMED Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-12,600
Closed -$1.16M – 2014
2024
Q2 		$1.16M Buy
+12,600
New +$1.17M 0.01% 1136

Other funds holding AMED

BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PCM
Pentwater Capital Management Naples, Florida $19.3B AUM 58.13% 1-Year Est. Return
Fidelity International
Fidelity International Hamilton, Bermuda $129B AUM 30.83% 1-Year Est. Return
AAM
Alpine Associates Management Palm Beach, Florida $1.7B AUM 97.55% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Norges Bank
Norges Bank Oslo, Norway $935B AUM
UBS Group
UBS Group Zurich, Switzerland $666B AUM 30.12% 1-Year Est. Return
TAL
TIG Advisors LLC New York $2.16B AUM 72.99% 1-Year Est. Return
Qube Research & Technologies (QRT)
Qube Research & Technologies (QRT) London, United Kingdom $89.9B AUM 20.22% 1-Year Est. Return

Schonfeld Strategic Advisors's AMED Position: Q2 2025 in Review

Schonfeld Strategic Advisors sold out of Amedisys (AMED) in Q2 2025, closing a stake of 4,500 shares — an estimated $417K sold.

Schonfeld Strategic Advisors first reported a position in AMED in Q4 2018 and held it in 14 quarters. The position peaked at $3.08M in Q3 2021. 319 funds tracked by Wall St. Rank hold AMED as of Q2 2025.

  • Schonfeld Strategic Advisors reported no remaining Amedisys position as of Q2 2025 after selling out during the quarter.
  • Schonfeld Strategic Advisors sold 4,500 Amedisys shares in Q2 2025, an estimated $417K.
  • Schonfeld Strategic Advisors first reported a position in Amedisys in Q4 2018 and held it in 14 quarters.
  • Schonfeld Strategic Advisors's Amedisys position peaked at $3.08M in Q3 2021.
  • 319 funds tracked by Wall St. Rank held Amedisys as of Q2 2025.

Based on Schonfeld Strategic Advisors's 13F filing for Q2 2025, filed 14 Aug 2025.